Celldex Therapeutics (CLDX) Tops Q1 EPS by 3c

Celldex Therapeutics (NASDAQ: CLDX) reported Q1 EPS of ($0.33), $0.03 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $406 thousand versus the consensus estimate of $460 thousand.

For earnings history and earnings-related data on (CLDX) click here.

You May Also Be Interested In

• AI and earnings keep driving markets as focus shifts to Trump-Xi summit
• AutoZone (AZO) Tops Q4 EPS by $1.76, Misses on Revenue
• Celldex's barzolvolimab meets Phase 3 endpoints in chronic hives trial